Abstract
Correctly identifying candidate drugs for protein targets is crucial for drug discovery. Despite the importance of this problem for the pharmaceutical industry, chemical screening remains a challenging task, and drug-target misidentification may contribute to failures in drug development. In their recent study, Sauer and colleagues (Holbrook-Smith et al, 2022) demonstrate proof-of-concept for a new way to identify drug-target interactions using high-throughput metabolomics, potentially paving the way towards a universal method for predicting drug-target relationships.